Global Alternative Proteins Market was valued at USD XX Billion in the year 2021. Global Alternative Proteins Market is further estimated to grow at a CAGR of XX% from 2022 to 2030 it will reach USD XX Billion by the year 2030. The North America region holds the highest market share in 2021 and the Asia Pacific is considered as the fastest growing market in the forecasted period. At a country level, US, China are projected to grow strongly in the coming years due to increasing density of population and funding through Research and Development.
The Global Alternative Proteins Report 2022-2030 covers market opportunities and challenges, key market regulations’ information, analysis of new products from the market players and key market trends, market share analysis for key players, supply chain and value chain analysis, product and Material trends, pricing analysis, emerging applications, technologies and major recent developments. This information has also been provided for the major country markets in these regions. Market shares, size and growth potential are assessed for these major country markets. Market opportunities, challenges, government regulations, market share analysis by major competitors, recent major market developments (product launches, M&A, partnerships, etc.) and other information have been covered for the major country markets listed in this section.
On the basis of Type, the market is divided as Emerging Alternative Protein, Adolescent Alternative Protein, Matured Alternative Protein. In which Emerging Alternative Protein for the largest market share due to increasing demand in future market trends. Regional breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and ROW.
Market player analysis of major companies such as Archer Daniels Midland Company, Cargill, Incorporated, Roquette Freres, Ingredion Incorporated, Kerry Group, E.I. Dupont De Nemours and Company, Now Foods, Tate & Lyle Plc , Axiom Foods Inc., Burcon NutraScience Corporation, Beneo GmbH, Glanbia Plc, Sotexpro, CHS Inc, AgriProtein , Ynsect, and Enterra Feed Corporation, among others...

1 INTRODUCTION
1.1 OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY DATA
1.2.2 PRIMARY DATA
1.2.3 MARKET SIZE ESTIMATION
1.2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.3 STAKEHOLDERS
1.4 RESEARCH ASSUMPTIONS
1.5 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 OPPORTUNITIES MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 VALUE CHAIN ANALYSIS
3.6 DEMAND SIDE ANALYSIS
3.7 SUPPLY SIDE ANALYSIS
3.8 PORTER’S FIVE FORCES MODEL
3.8.1 DEGREE OF COMPETITION
3.8.2 BARGAINING POWER OF BUYERS
3.8.3 BARGAINING POWER OF SUPPLIERS
3.8.4 THREAT FROM SUBSTITUTES
3.8.5 THREAT FROM NEW ENTRANTS
4 INDUSTRY TRENDS
4.1 PRODUCT LIFE CYCLE
4.2 NEW MARKET ENTRY STRATEGY
4.3 PESTEL ANALYSIS
4.4 PRICING ANALYSIS
4.5 TRADE DATA
4.6 TECHNOLOGICAL OVERVIEW
4.7 FUTURE OUTLOOK MARKET TRENDS
4.8 MACRO-ECONOMIC VARIABLES (DEPENDENT AND INDEPENDENT VARIABLES)
4.9 MULTIFACTOR BASED SENSITIVITY ANALYSIS
4.10 REGRESSION MATRIX
4.11 COVID-19 IMPACT ANALYSIS
4.12 GE MATRIX
5 ALTERNATIVE PROTEINS TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2016-2020
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 EMERGING ALTERNATIVE PROTEINS
5.5.1 INSECT PROTEINS
5.5.2 ALGAE PROTEINS
5.5.3 DUCKWEED PROTEINS
5.6 ADOLESCENT ALTERNATIVE PROTEINS
5.6.1 PEA PROTEINS
5.6.2 RICE PROTEINS
5.6.3 CORN PROTEINS
5.6.4 POTATO PROTEINS
5.6.5 OTHERS
5.7 MATURE ALTERNATIVE PROTEINS
5.7.1 SOY PROTEINS
5.7.2 WHEAT PROTEINS
5.7.3 CANOLA PROTEINS
5.7.4 MYCOPROTEINS
5.7.5 MUSHROOMS PROTEINS
5.7.6 OTHERS
6 ALTERNATIVE PROTEINS SOURCE ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET SOURCE ANALYSIS, 2016-2020
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 PLANT-BASED
6.6 INSECT-BASED
6.7 MICROBIAL-BASED
6.7.1 BACTERIA
6.7.2 YEAST
6.7.3 ALGAE
6.7.4 OTHERS
7 ALTERNATIVE PROTEINS END USE ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET END USE ANALYSIS, 2016-2020
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 MEAT ANALOGS
7.6 BAKERY
7.7 DAIRY ALTERNATIVES
7.8 CEREALS & SNACKS
7.9 BEVERAGES
7.10 OTHERS
8 ALTERNATIVE PROTEINS MARKET APPLICATION ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 INSECT PROTEIN-BASED PRODUCTS
8.5.1 VALUE-ADDED WHOLE INSECTS
8.5.2 ANIMAL AND PET FEED PRODUCTS
8.5.3 VALUE-ADDED INSECT POWDER
8.5.4 INSECT PROTEIN BARS AND PROTEIN SHAKES
8.5.5 INSECT BAKED PRODUCTS AND SNACKS
8.5.6 INSECT CONFECTIONARIES
8.5.7 INSECT BEVERAGES
8.5.8 OTHERS
8.6 PLANT PROTEIN-BASED PRODUCTS
8.6.1 FOODS AND BEVERAGES
8.6.2 ANIMAL FEED
8.6.3 NUTRITION & HEALTH SUPPLEMENTS
8.6.4 PHARMACEUTICALS
8.6.5 OTHERS
8.7 MICROBIAL PROTEIN-BASED PRODUCTS
8.7.1 FOOD AND BEVERAGE
8.7.2 ANIMAL FEED
8.7.3 NUTRACEUTICAL
8.7.4 COSMETICS
8.7.5 CHEMICALS
8.7.6 OTHERS
9 GLOBAL ALTERNATIVE PROTEINS REGIONAL ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
9.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
9.2.3 Y-O-Y GROWTH TREND ANALYSIS
9.2.3.1 U.S.
9.2.3.2 Canada
9.2.3.3 Mexico
9.3 ASIA-PACIFIC
9.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
9.3.2 Y-O-Y GROWTH TREND ANALYSIS
9.3.2.1 China
9.3.2.2 Japan
9.3.2.3 Korea
9.3.2.4 India
9.3.2.5 Southeast Asia
9.4 MIDDLE EAST AND AFRICA
9.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
9.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
9.4.3 Y-O-Y GROWTH TREND ANALYSIS
9.4.3.1 Saudi Arabia
9.4.3.2 UAE
9.4.3.3 Egypt
9.4.3.4 Nigeria
9.4.3.5 South Africa
9.5 EUROPE
9.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
9.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
9.5.3 Y-O-Y GROWTH TREND ANALYSIS
9.5.3.1 Germany
9.5.3.2 France
9.5.3.3 UK
9.5.3.4 Russia
9.5.3.5 Italy
9.6 LATIN AMERICA
9.6.1 LATIN AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
9.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
9.6.3 Y-O-Y GROWTH TREND ANALYSIS
9.6.3.1 Brazil
9.6.3.2 Argentina
9.6.3.3 Columbia
10 MARKET PLAYERS
10.1 ARCHER DANIELS MIDLAND COMPANY
10.1.1 BUSINESS OVERVIEW:
10.1.2 PRODUCT PORTFOLIO
10.1.3 RECENT DEVELOPMENTS
10.1.4 SWOT ANALYSIS:
10.2 CARGILL, INCORPORATED
10.3 ROQUETTE FRERES LE ROMAIN
10.4 INGREDION INCORPORATED
10.5 KERRY GROUP
10.6 E.I. DU PONT DE NEMOURS AND COMPANY
10.7 NOW FOODS
10.8 TATE & LYLE PLC
10.9 AXIOM FOODS INC.
10.10 BURCON NUTRASCIENCE CORPORATION
10.11 BENEO GMBH (A PART OF SUDZUCKER AG)
10.12 GLANBIA PLC
10.13 SOTEXPRO
10.14 FARBEST BRANDS
10.15 CHS INC.
10.16 AGRIPROTEIN
10.17 YNSECT SAS
10.18 ENTERRA FEED CORPORATION
10.19 PROTIX B.V.
10.20 PROTI-FARM HOLDING NV
10.21 ENTOMO FARMS
10.22 GLOBAL BUGS ASIA CO., LTD.
10.23 ASPIRE FOOD GROUP
10.24 TINY FARMS
10.25 ENTOCUBE LTD.
10.26 ENVIROFLIGHT CORPORATIO
10.27 HAOCHENG MEALWORM INC.
10.28 JR UNIQUE FOODS LTD.
10.29 ARMSTRONG CRICKET GEORGIA
10.30 ROCKY MOUNTAIN MICRO RANCH
10.31 DIC CORPORATION
10.32 CELLANA INC.
10.33 TAIWAN CHLORELLA MANUFACTURING COMPANY
10.34 CYANOTECH CORPORATION
10.35 BLUEBIOTECH INTERNATIONAL GMBH
10.36 ALGATECHOLOGIES LTD.
10.37 POND TECHNOLOGIES INC.
10.38 E.I.D.-PARRY (INDIA) LIMITED
10.39 TIANJIN NORLAND BIOTECH CO., LTD.
10.40 ALGAECAN BIOTECH LTD.
10.41 CORBION N.V.
10.42 SUN CHLORELLA CORPORATION
10.43 PLANTIBLE FOODS, INC.
10.44 MYCOTECHNOLOGY INC.
10.45 3F BIO LTD.
10.46 FEBICO GROUP (FAR EAST BIO-TEC. CO. LTD.)
10.47 ROQUETTE KLOTZE GMBH & CO. KG
10.48 YAEYAMA SHOKUSAN CO., LTD.
10.49 FAR EAST MICROALGAE IND, CO., LTD. (FEMICO)
10.50 PARABEL INC.
11 ABOUT US

TABLE 1 ALTERNATIVE PROTEINS REGIONAL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 2 GLOBAL ALTERNATIVE PROTEINS MARKET, 2021–2030, (USD MILLION)
TABLE 3 ALTERNATIVE PROTEINS CURRENT AND FUTURE REGIONAL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 4 GLOBAL ALTERNATIVE PROTEINS HISTORICAL MARKET TYPE ANALYSIS, 2016-2020, (USD MILLION)
TABLE 5 ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 6 GLOBAL ALTERNATIVE PROTEINS HISTORICAL MARKET SOURCE ANALYSIS, 2016-2020, (USD MILLION)
TABLE 7 ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 8 GLOBAL ALTERNATIVE PROTEINS HISTORICAL MARKET END USE ANALYSIS, 2016-2020, (USD MILLION)
TABLE 9 ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 10 GLOBAL ALTERNATIVE PROTEINS HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020, (USD MILLION)
TABLE 11 ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 12 NORTH AMERICA ALTERNATIVE PROTEINS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 13 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 14 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 15 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 16 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 17 U.S. ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2016–2021
TABLE 18 U.S. ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 19 U.S. ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 20 CANADA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 21 CANADA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 22 MEXICO ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 23 MEXICO ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 24 APAC ALTERNATIVE PROTEINS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 25 ASIA-PACIFIC ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 26 ASIA-PACIFIC ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 29 CHINA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 30 CHINA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 31 JAPAN ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 32 JAPAN ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 33 KOREA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 34 KOREA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 35 INDIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 36 INDIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 37 SOUTHEAST ASIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 38 SOUTHEAST ASIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 44 SAUDI ARABIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 45 SAUDI ARABIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 46 UAE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 47 UAE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 48 EGYPT ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 49 EGYPT ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 50 NIGERIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 51 NIGERIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 52 SOUTH AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 53 SOUTH AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 54 EUROPE ALTERNATIVE PROTEINS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 55 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 56 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 57 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 58 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 59 GERMANY ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 60 GERMANY ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 61 FRANCE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 62 FRANCE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 63 UK ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 64 UK ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 65 RUSSIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 66 RUSSIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 67 ITALY ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 68 ITALY ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 69 LATIN AMERICA ALTERNATIVE PROTEINS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 70 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 71 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 72 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 73 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 74 BRAZIL ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 75 BRAZIL ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 76 ARGENTINA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 77 ARGENTINA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 78 COLUMBIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 79 COLUMBIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 1 GLOBAL ALTERNATIVE PROTEINS MARKET, 2021–2030, (USD MILLION)
FIGURE 2 RESEARCH METHODOLOGY
FIGURE 3 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 4 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 5 MARKET OVERVIEW
FIGURE 6 SWOT ANALYSIS
FIGURE 7 MARKET SHARE ANALYSIS
FIGURE 8 SUPPLY CHAIN ANALYSIS
FIGURE 9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 10 ALTERNATIVE PROTEINS TYPE ANALYSIS
FIGURE 11 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 12 ALTERNATIVE PROTEINS SOURCE ANALYSIS
FIGURE 13 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 14 ALTERNATIVE PROTEINS END USE ANALYSIS
FIGURE 15 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 16 ALTERNATIVE PROTEINS APPLICATION ANALYSIS
FIGURE 17 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 18 GLOBAL ALTERNATIVE PROTEINS CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 19 MARKET OVERVIEW, REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 20 MARKET SHARE BY COUNTRY
FIGURE 21 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 22 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 23 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 24 NORTH AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 25 U.S. ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 26 U.S. ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 27 CANADA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 28 CANADA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 29 MEXICO ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 30 MEXICO ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 31 MARKET SHARE BY COUNTRY
FIGURE 32 APAC ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 33 APAC ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 34 APAC ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 35 APAC ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 36 CHINA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 37 CHINA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 38 JAPAN ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 39 JAPAN ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 40 KOREA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 41 KOREA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 42 INDIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 43 INDIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 44 SOUTHEAST ASIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 45 SOUTHEAST ASIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 46 MARKET SHARE BY COUNTRY
FIGURE 47 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 49 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 50 MIDDLE EAST AND AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 51 SAUDI ARABIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 52 SAUDI ARABIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 53 UAE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 54 UAE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 55 EGYPT ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 56 EGYPT ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 57 NIGERIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 58 NIGERIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 59 SOUTH AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 60 SOUTH AFRICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 61 MARKET SHARE BY COUNTRY
FIGURE 62 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 63 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 64 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 65 EUROPE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 66 GERMANY ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 67 GERMANY ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 68 FRANCE ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 69 FRANCE ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 70 UK ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 71 UK ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 72 RUSSIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 73 RUSSIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 74 ITALY ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 75 ITALY ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 76 MARKET SHARE BY COUNTRY
FIGURE 77 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 78 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE SOURCE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 79 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE END USE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 80 LATIN AMERICA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 81 BRAZIL ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 82 BRAZIL ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 83 ARGENTINA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 84 ARGENTINA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 85 COLUMBIA ALTERNATIVE PROTEINS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 86 COLUMBIA ALTERNATIVE PROTEINS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 87 FINANCIAL OVERVIEW: